Timothy Baxter v. Robert Kennedy, Jr.

136 F.4th 70
CourtCourt of Appeals for the Fourth Circuit
DecidedApril 29, 2025
Docket24-1203
StatusPublished

This text of 136 F.4th 70 (Timothy Baxter v. Robert Kennedy, Jr.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Timothy Baxter v. Robert Kennedy, Jr., 136 F.4th 70 (4th Cir. 2025).

Opinion

USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 1 of 31

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 24-1203

DR. TIMOTHY BAXTER,

Plaintiff – Appellant,

v.

ROBERT F. KENNEDY, JR., in his official capacity as Secretary, Department of Health and Human Services; JULIET T. HODGKINS, in her official capacity as Acting Inspector General, Department of Health and Human Services,

Defendants – Appellees.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Roderick Charles Young, District Judge. (3:23-cv-00092-RCY)

Argued: October 29, 2024 Decided: April 29, 2025

Before AGEE, RICHARDSON, and BERNER, Circuit Judges.

Affirmed by published opinion. Judge Richardson wrote the opinion, in which Judge Agee and Judge Berner joined.

ARGUED: Thomas M. Johnson, Jr., WILEY REIN LLP, Washington, D.C., for Appellant. Rebecca Sara Levenson, OFFICE OF THE UNITED STATES ATTORNEY, Alexandria, Virginia, for Appellees. ON BRIEF: Brandon J. Moss, Jeremy J. Broggi, Michael J. Showalter, William Turner, WILEY REIN LLP, Washington, D.C., for Appellant. Maddie J. Bainer, Senior Counsel, Office of Counsel to the Inspector General, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, Washington, D.C.; Jessica D. Aber, United States Attorney, Jonathan T. Lucier, Assistant USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 2 of 31

United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Richmond, Virginia, for Appellees.

2 USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 3 of 31

RICHARDSON, Circuit Judge:

This appeal turns on a little-known provision of the Social Security Act, 42 U.S.C.

§ 1320a-7(a). That subsection adds an additional consequence to certain healthcare-related

crimes by commanding the Health Secretary to ban persons who commit them from

working with federal healthcare programs. Among the covered offenses are those “related

to the delivery of an item or service . . . under any State health care program.” 42 U.S.C.

§ 1320a-7(a)(1).

Dr. Timothy Baxter faces the business end of such a ban. While working for a

pharmaceutical company called Indivior, Baxter distributed misinformation to

Massachusetts’s Medicaid program about the safety of new opioid drugs. That is a federal

offense. And when federal prosecutors caught up with him, Baxter pleaded guilty. On the

back of that prior offense, the Secretary subsequently banned him from working with

federal healthcare programs for five years.

Now, Baxter challenges his exclusion. He floats an interpretation of the additional-

consequence statute’s subsection (a) on which that subsection mandates exclusion only if

his crime categorically relates to the delivery of an item or service under a state healthcare

program. No federal court of appeals has adopted this argument. We will not be the first.

The text and context of the mandatory-exclusion subsection make clear that it looks to what

the individual actually did, not to offenses in the abstract. It thus requires only that the

actual conduct be “related to” the specific acts listed in the statute. Baxter’s actual conduct

satisfies that requirement and thereby triggered mandatory exclusion.

3 USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 4 of 31

I. Background

A. At Indivior, Baxter Misbrands Opioids

Baxter used to be the Global Medical Director at Indivior, a pharmaceutical

company that produces the opioid drugs Suboxone and Subutex. 1 Suboxone and Subutex

are designed to help wean those who struggle with addiction off other, more dangerous

opioids. Both drugs have saved lives. But they aren’t risk-free. Like the drugs they seek

to replace, these drugs still contain opioids. So one of the drugs—Suboxone—contains a

second substance that induces withdrawal symptoms when insufflated or injected. Yet

though Suboxone reduces the risk of adult misuse this way, it still endangers children who

mistakenly take the pills.

To address this problem, Indivior introduced a new drug called Suboxone Film. As

the name suggests, Suboxone Film is the same drug. But rather than being packaged as

pills, it’s a strip that dissolves under the tongue. Indivior hoped that children would be less

likely to take individually wrapped film by accident than to swallow pills (thinking they

were food or candy).

This case began with Indivior’s efforts to sell Suboxone Film in Massachusetts.

Doing that depended on MassHealth, Massachusetts’s state-run Medicaid program. If

MassHealth put a drug on its “preferred” drug list, more doctors would prescribe it—or so

the theory went. And getting Suboxone Film on that list depended on persuading

MassHealth that Film was better than its competition. Indivior’s plan was straightforward:

1 Indivior is a successor entity to Reckitt Benckiser Pharmaceuticals. 4 USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 5 of 31

persuade MassHealth to cover more Suboxone Film prescriptions by giving MassHealth

data showing that Film had better pediatric-exposure figures than its predecessors.

But in trying to do that, Indivior ran into a problem. The data didn’t show what

Indivior wanted it to show. Rather than proving that Suboxone Film posed the lowest risk

to children, the data suggested that Subutex—the oldest drug in Indivior’s stable—posed

the lowest risk to children.

So Indivior doctored the numbers. It added the child-exposure rates for both pills—

Suboxone and Subutex—and compared the sum to Suboxone Film’s child-exposure rate.

This incorrectly suggested that Film was less risky than either older drug. Then Indivior

employees packaged the data into a chart and sent it to MassHealth. Eventually,

MassHealth placed Suboxone Film on its “preferred” list, making it available to more

patients.

B. Baxter Pleads Guilty as a Responsible Corporate Officer

In 2020, federal prosecutors charged Baxter with misdemeanor drug misbranding in

violation of 21 U.S.C. § 331(a). That statute makes it a federal crime to cause “[t]he

introduction or delivery for introduction into interstate commerce of any . . . drug . . . that

is adulterated or misbranded.” Id. And a drug counts as misbranded if its manufacturer

distributes “exhibits, literature, . . . or visual matter,” 21 C.F.R. § 202.1(l)(2), that are “false

or misleading in any particular,” 21 U.S.C. § 352(a)(1).

Baxter faced liability under that statute even though he didn’t personally prepare or

send the misleading data. Under what we have called the “responsible corporate officer

doctrine,” United States v. Ming Hong, 242 F.3d 528, 531 (4th Cir. 2001), he was liable

5 USCA4 Appeal: 24-1203 Doc: 37 Filed: 04/29/2025 Pg: 6 of 31

for what his company did just because of his supervisory role—even if he didn’t know

about the misbranding or do it himself. United States v. Park, 421 U.S. 658, 672–73

(1975). 2

Baxter pleaded guilty. As part of his plea agreement, he admitted that he “caused

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Jordan v. De George
341 U.S. 223 (Supreme Court, 1951)
Morissette v. United States
342 U.S. 246 (Supreme Court, 1952)
Morrissey v. Brewer
408 U.S. 471 (Supreme Court, 1972)
United States v. Park
421 U.S. 658 (Supreme Court, 1975)
Cleveland Board of Education v. Loudermill
470 U.S. 532 (Supreme Court, 1985)
Taylor v. United States
495 U.S. 575 (Supreme Court, 1990)
Morales v. Trans World Airlines, Inc.
504 U.S. 374 (Supreme Court, 1992)
Almendarez-Torres v. United States
523 U.S. 224 (Supreme Court, 1998)
Leocal v. Ashcroft
543 U.S. 1 (Supreme Court, 2004)
Jama v. Immigration and Customs Enforcement
543 U.S. 335 (Supreme Court, 2005)
Shepard v. United States
544 U.S. 13 (Supreme Court, 2005)
Gonzales v. Duenas-Alvarez
549 U.S. 183 (Supreme Court, 2007)
Begay v. United States
553 U.S. 137 (Supreme Court, 2008)
Nijhawan v. Holder
557 U.S. 29 (Supreme Court, 2009)
United States v. Hayes
555 U.S. 415 (Supreme Court, 2009)
United States v. Meade
175 F.3d 215 (First Circuit, 1999)
Ram v. Heckler
792 F.2d 444 (Fourth Circuit, 1986)
Ricardo Prudencio v. Eric Holder, Jr.
669 F.3d 472 (Fourth Circuit, 2012)
Kawashima v. Holder
132 S. Ct. 1166 (Supreme Court, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
136 F.4th 70, Counsel Stack Legal Research, https://law.counselstack.com/opinion/timothy-baxter-v-robert-kennedy-jr-ca4-2025.